[Skip to Content]
[Skip to Content Landing]
November 1976

Adjuvant Nitrosourea Therapy for Glioblastoma

Author Affiliations

From the Brain Tumor Study Group, College of Physicians and Surgeons, Columbia University, and the New York Neurological Institute, Columbia Presbyterian Medical Center. Other members of the Study Group are listed on p 750.

Arch Neurol. 1976;33(11):745-750. doi:10.1001/archneur.1976.00500110013003

• An attempt was made to evaluate the potential advantages of chemotherapy in the treatment of 62 patients with glioblastoma. Twenty-four of the 62 patients received adjuvant nitrosourea chemotherapy with carmustine (BCNU), lomustine (CCNU), or semustine (methyl CCNU) in addition to surgery and radiotherapy. Thirty-three of the 62 patients were involved in a controlled, prospective, randomly allocated study. Quality or quantity of survival was not prolonged in patients who received chemotherapy. Age greater than 64 years, a severe postoperative neurological deficit, or the onset of symptoms less than 12 months prior to surgery were associated with a worse prognosis. The valid evaluation of the effect of a form of treatment on survival in patients with glioblastoma is contingent on the rigorous avoidance of preselected factors that may predispose the treated group to a more favorable prognosis.